At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multiple Dose Titration Study in Chinese Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Tirzepatide
In Brief
A Phase 1 clinical trial evaluating Tirzepatide and Placebo for Diabetes Mellitus, Type 2. Completed, enrolled 24 participants across 2 sites.
Detailed Summary
The main purpose of this study is to learn more about the safety and side effects of tirzepatide in Chinese participants with type 2 diabetes mellitus. The study will also measure how much tirzepatide gets into the bloodstream and how long it takes the body to remove it. The study will last about six or eight months for each participant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedJan 2020
Enrollment StartOct 2020
Primary CompletionAug 2021
TodayJul 2026
First PostedJan 22, 2020
Enrollment StartOct 21, 2020
Primary CompletionAug 17, 2021
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 6.4 years ago
Interventions
Tirzepatidedrug
Administered SC
Placebodrug
Administered SC